Fosun International Ltd cut its position in Pfizer Inc. (NYSE:PFE) by 52.8% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 9,720 shares of the biopharmaceutical company’s stock after selling 10,880 shares during the quarter. Fosun International Ltd’s holdings in Pfizer were worth $318,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also recently modified their holdings of the company. Orser Capital Management LLC raised its position in shares of Pfizer by 2.7% in the fourth quarter. Orser Capital Management LLC now owns 10,990 shares of the biopharmaceutical company’s stock valued at $428,000 after purchasing an additional 290 shares during the period. S.E.E.D. Planning Group LLC purchased a new position in Pfizer in the 4th quarter valued at approximately $479,000. Campbell & CO Investment Adviser LLC bought a new stake in Pfizer during the 4th quarter valued at $490,000. Perennial Advisors LLC bought a new stake in Pfizer during the 4th quarter valued at $216,000. Finally, Harel Insurance Investments & Financial Services Ltd. purchased a new stake in shares of Pfizer during the fourth quarter worth $261,000. 69.91% of the stock is currently owned by hedge funds and other institutional investors.
NYSE PFE traded up $0.24 during trading hours on Friday, reaching $37.50. 14,885,114 shares of the stock traded hands, compared to its average volume of 22,354,300. The stock has a 50 day simple moving average of $36.51 and a two-hundred day simple moving average of $36.84. Pfizer Inc. has a 1 year low of $27.88 and a 1 year high of $44.56. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.02 and a quick ratio of 0.78. The company has a market cap of $206.97 billion, a price-to-earnings ratio of 13.39, a price-to-earnings-growth ratio of 2.72 and a beta of 0.71.
Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, April 28th. The biopharmaceutical company reported $0.80 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.71 by $0.09. The firm had revenue of $12.03 billion during the quarter, compared to analysts’ expectations of $11.38 billion. Pfizer had a return on equity of 25.76% and a net margin of 31.17%. The company’s revenue for the quarter was down 8.3% compared to the same quarter last year. During the same period in the prior year, the business earned $0.85 EPS. On average, sell-side analysts forecast that Pfizer Inc. will post 2.81 EPS for the current fiscal year.
The firm also recently declared a quarterly dividend, which will be paid on Friday, June 5th. Shareholders of record on Friday, May 8th will be given a dividend of $0.38 per share. This represents a $1.52 dividend on an annualized basis and a yield of 4.05%. The ex-dividend date is Thursday, May 7th. Pfizer’s payout ratio is currently 51.53%.
PFE has been the topic of a number of analyst reports. Barclays boosted their price objective on Pfizer from $36.00 to $37.00 and gave the company an “equal weight” rating in a research note on Wednesday, April 29th. JPMorgan Chase & Co. reissued a “neutral” rating and issued a $37.00 price target on shares of Pfizer in a report on Tuesday, January 28th. Cantor Fitzgerald restated a “buy” rating and issued a $53.00 price objective on shares of Pfizer in a research report on Thursday, March 19th. Zacks Investment Research lowered shares of Pfizer from a “buy” rating to a “hold” rating and set a $40.00 target price on the stock. in a report on Monday, May 4th. Finally, Standpoint Research raised shares of Pfizer from a “hold” rating to a “buy” rating in a report on Thursday, February 27th. Nine investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company. The company has an average rating of “Hold” and a consensus target price of $41.28.
In related news, major shareholder Pfizer Inc bought 312,500 shares of the stock in a transaction dated Monday, March 16th. The stock was bought at an average price of $16.00 per share, with a total value of $5,000,000.00. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, SVP Jennifer B. Damico sold 2,181 shares of the stock in a transaction that occurred on Wednesday, April 29th. The shares were sold at an average price of $38.35, for a total value of $83,641.35. Following the sale, the senior vice president now directly owns 9,647 shares of the company’s stock, valued at approximately $369,962.45. The disclosure for this sale can be found here. Insiders own 0.08% of the company’s stock.
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.
Further Reading: S&P 500 Index
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.